Pediatric Rheumatology

, 9:O38 | Cite as

Rilonacept (IL-1 TRAP) for treatment of colchicine resistant familial mediterranean fever (FMF): a randomized, multicenter double-blinded, alternating treatment trial

  • PJ Hashkes
  • SJ Spalding
  • EH Giannini
  • B Huang
  • G Park
  • KS Barron
  • MH Weisman
  • N Pashinian
  • AO Reiff
  • J Samuels
  • D Wright
  • DL Kastner
  • DJ Lovell
Open Access
Oral presentation

Keywords

Placebo Colchicine Familial Mediterranean Fever Signed Rank Injection Site Reaction 

Background

There is no current treatment alternative for patients with FMF whose disease is resistant to, or do not tolerate colchicine. Since pyrin has an important role in IL-1β regulation we hypothesize that IL-1 inhibition will decrease the number of FMF attacks in these patients.

Aim

To determine if rilonacept, a fusion protein that binds and neutralizes IL-1, decreases the number of FMF attacks compared to placebo.

Methods

Subjects were FMF patients ≥4 years of age recruited at 6 U.S. sites, who had at least 1 FMF attack per month despite receiving adequate doses of, or who were intolerant of colchicine. Subjects received two 3-month courses of rilonacept (Arm A) at 2.2 mg/kg (max 160 mg) by weekly SC injection and two 3-month courses of placebo (Arm B). Patients were randomized to 1 of 4 treatment sequences (ABAB, BABA, ABBA, BAAB). Escape visits were allowed to permit switching arms (blinding was maintained) for patients with at least 2 attacks within a course. The primary outcome was the difference of FMF attacks between rilonacept and placebo courses with responders defined as subjects with a >40% difference. Results were analyzed by paired t-and signed rank tests.

Results

Fourteen subjects were randomized, 8 males and 6 females, mean (±SD) age 24.4±11.8 years (range 4.5-47.3; 4 patients <18 years), disease duration 17.5±12.6 yrs, with a baseline of 3.1±2.0 attacks per month. Eleven completed the full study and 3 dropped out (1 due to lack of efficacy, 1 due to distance from study site and 1 lost to follow-up). Among 12 patients who completed at least 2 treatment courses the mean number of attacks per month on rilonacept was 1.0±1.2 vs. 1.8±0.9 on placebo (P=0.021 by paired t-test and 0.027 by signed rank test). There were 8 responders; all 4 non-responders were adults. There were 2 respiratory infection SAEs, 1 on rilonacept and 1 on placebo. Injections site reactions were significantly more frequent with rilonacept but no differences were seen in other adverse events, including infections.

Conclusions

Rilonacept significantly reduced the number of FMF attacks and had an acceptable safety profile. IL-1 inhibition is a treatment option for most (especially children) colchicine resistant FMF patients.

Copyright information

© Hashkes et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Authors and Affiliations

  • PJ Hashkes
    • 1
    • 8
  • SJ Spalding
    • 1
  • EH Giannini
    • 2
  • B Huang
    • 2
  • G Park
    • 3
  • KS Barron
    • 3
  • MH Weisman
    • 4
  • N Pashinian
    • 4
  • AO Reiff
    • 5
  • J Samuels
    • 6
  • D Wright
    • 7
  • DL Kastner
    • 3
  • DJ Lovell
    • 2
  1. 1.Cleveland Clinic FoundationUSA
  2. 2.Cincinnati Children's Hospital Medical CenterUSA
  3. 3.National Institutes of HealthUSA
  4. 4.Cedar-Sinai Medical CenterUSA
  5. 5.Children’s Hospital of Los AngelesUSA
  6. 6.NYU Langone Hospital for Joint DiseasesUSA
  7. 7.Children’s Hospital Central CaliforniaUSA
  8. 8.Shaare Zedek Medical CenterJerusalemIsrael

Personalised recommendations